2017, EBITDA and Specific Risk - Business Valuation Zone

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2017

EBITDA

Specific Risk

PARAMETERS UPDATE P5.4

Equidam

NOVEMBER 22, 2021

We base our estimates on real transactions by country since November 1st, 2017. You can refer to the table at this link to see how they will change for your country specifically. 2 | Industry EBITDA multiples used in the VC and DCF with multiple. 3 | Discount rate components used in the two DCF methods.

EBITDA

EBITDA Specific Risk Technology Marketability

MAEjor Ruling: Delaware Court of Chancery Finds Target Suffers Material Adverse Effect and Acquirer Could Back Out of Transaction

Cooley M&A

OCTOBER 29, 2018

In April 2017, Fresenius agreed to acquire Akorn, a US-based, Nasdaq-listed specialty manufacturer and marketer of generic prescription and over-the-counter pharmaceutical products, for $35 per share or approximately $4.75 The decline must also result from company-specific problems rather than industry-wide conditions.

Compliance

Compliance EBITDA Specific Risk Marketability

PARAMETERS UPDATE P5.4

MAEjor Ruling: Delaware Court of Chancery Finds Target Suffers Material Adverse Effect and Acquirer Could Back Out of Transaction

Stay Connected